Effects of Serenoa repens Alcohol Extract on Benign Prostate Hyperplasia
References
- 1. Hoke GP, McWilliams GW. Epidemiology of benign prostatic hyperplasia and comorbidities in racial and ethnic minority populations. Am J Med. 2008; 121(8 Suppl 2):S3-10. doi: 10.1016/j.amjmed.2008.05.021.10.1016/j.amjmed.2008.05.021
- 2. Patel ND, Parsons JK. Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. Indian J Urol. 2014; 30(2):170-6. doi: 10.4103/0970-1591.126900.10.4103/0970-1591.126900
- 3. Vuichoud C, Loughlin KR. Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol. 2015; 22 Suppl 1:1-6.
- 4. Jacobsen SJ, Girman CJ, Lieber MM. Natural history of benign prostatic hyperplasia. Urology. 2001; 58(6 Suppl 1):5-16; discussion 16.
- 5. Fitzpatrick JM. The natural history of benign prostatic hyperplasia. BJU Int. 2006; 97 Suppl 2:3-6; discussion 21-2. doi: 10.1111/j.1464-410X.2006.06097.x.10.1111/j.1464-410X.2006.06097.x
- 6. Barkin J. Benign prostatic hyperplasia and lower urinary tract symptoms: evidence and approaches for best case management. Can J Urol. 2011; 18 Suppl:14-9.
- 7. Alcaraz A, Carballido-Rodriguez J, Unda-Urzaiz M, et al. Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment--the QUALIPROST study. Int Urol Nephrol. 2016; 48(5):645-56. doi: 10.1007/s11255-015-1206-7.10.1007/s11255-015-1206-7
- 8. Elterman DS, Barkin J, Kaplan SA. Optimizing the management of benign prostatic hyperplasia. Ther Adv Urol. 2012; 4(2):77-83. doi: 10.1177/1756287212437361.
- 9. Fourcade RO, Lacoin F, Roupret M, et al. Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia. World J Urol. 2012; 30(3):419-26. doi: 10.1007/s00345-011-0756-2.10.1007/s00345-011-0756-2
- 10. Ryu YW, Lim SW, Kim JH, et al. Comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study. Urol Int. 2015; 94(2):187-93. doi: 10.1159/000366521.
- 11. Di Silverio F, Monti S, Sciarra A, et al. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate. 1998; 37(2):77-83. doi: 10.1002/(SICI)1097-0045(19981001)37:2<;77::AIDPROS3>3.0.CO;2-I.10.1002/(SICI)1097-0045(19981001)37:2<;77::AIDPROS3>3.0.CO;2-
- 12. Bayne CW, Donnelly F, Ross M, et al. Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH. Prostate. 1999; 40(4):232-41. doi: 10.1002/(SICI)1097-0045(19990901)40:4<;232::AID-PROS4>3.0.CO;2-0.10.1002/(SICI)1097-0045(19990901)40:4<;232::AID-PROS4>3.0.CO;2-0
- 13. Latil A, Libon C, Templier M, et al. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro. BJU Int. 2012; 110(6 Pt B):E301-7. doi: 10.1111/j.1464-410X.2012.11144.x.
- 14. Scaglione F, Lucini V, Pannacci M, et al. Comparison of the potency of 10 different brands of Serenoa repens extracts. Eur Rev Med Pharmacol Sci. 2012; 16(5):569-74.
- 15. Sirab N, Robert G, Fasolo V, et al. Lipidosterolic extract of Serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells. Int J Mol Sci. 2013; 14(7):14301-20. doi: 10.3390/ijms140714301.10.3390/ijms140714301
- 16. European Medicines Agency (2015) Committee on Herbal Medicinal Products (HMPC). Assessment report on Serenoa repens (W, Bartram) Small, fructus EMA/HMPC/137250/2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Herbal-HMPC_assessment_report/2014/12/WC500179593.pdf. Accessed May 2017.
- 17. Gratzke C, Bachmann A, Descazeaud A, et al. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. Eur Urol. 2015; 67(6):1099-109. doi: 10.1016/j.eururo.2014.12.038.10.1016/j.eururo.2014.12.038
- 18. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol. 2003; 170(2 Pt 1):530-47. doi: 10.1097/01.ju.0000078083.38675.79.10.1097/01.ju.0000078083.38675.79
- 19. Andriole GL, McCullum-Hill C, Sandhu GS, et al.; CAMUS Study Group. The effect of increasing doses of saw palmetto fruit extract on serum prostate specific antigen: analysis of the CAMUS randomized trial. J Urol. 2013; 189(2):486-92. doi: 10.1016/j.juro.2012.09.037.10.1016/j.juro.2012.09.037
- 20. Fagelman E, Lowe FC. Saw Palmetto Berry as a Treatment for BPH. Rev Urol. 2001 Summer; 3(3):134-8.
- 21. Kim SW. Phytotherapy: emerging therapeutic option in urologic disease. Transl Androl Urol. 2012; 1(3):181-91. doi: 10.3978/j.issn.2223-4683.2012.05.10.10.3978/j.issn.2223-4683.2012.05.10
- 22. Argirović A, Argirović D. Does the Addition of Serenoa Repens to Tamsulosin Improve Its Therapeutical Efficacy in Benign Prostatic Hyperplasia? Vojnosanit Pregl. 2013; 70(12):1091-6.
- 23. Geavlete P, Multescu R, Geavlete B. Serenoa repens extract in the treatment of benign prostatic hyperplasia. Ther Adv Urol. 2011; 3(4):193-8. doi: 10.1177/1756287211418725.
- 24. Bent S, Kane C, Shinohara K, et al. Saw palmetto for benign prostatic hyperplasia. NEJM. 2006; 354(6):557-66. doi: 10.1056/NEJMoa053085.10.1056/NEJMoa053085
- 25. Barry MJ, Meleth S, Lee JY, et al. Effect of increasing doses of Saw palmetto extract on lower urinary tract symptoms. JAMA. 2011; 306(12):1344-51. doi: 10.1001/jama.2011.1364.10.1001/jama.2011.1364
- 26. MacDonald R, Tacklind JW, Rutks I, et al. Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review. BJU Int. 2012; 109(12):1756-61. doi: 10.1111/j.1464-410X.2012.11172.x.10.1111/j.1464-410X.2012.11172.x
- 27. Ooi SL, Pak SC. Serenoa repens for Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: Current Evidence and its Clinical Implications in Naturopathic Medicine. J Altern Complement Med. 2017 Apr 24. doi: 10.1089/acm.2016.0302.10.1089/acm.2016.0302
- 28. Suzuki M, Ito Y, Fujino T, et al. Pharmacological effects of saw palmetto extract in the lower urinary tract. Acta Pharmacol Sin. 2009; 30(3):227-81. doi: 10.1038/aps.2009.1.10.1038/aps.2009.1
- 29. De Monte C, Carradori S, Granese A, et al. Modern extraction techniques and their impact on the pharmacological profile of Serenoa repens extracts for the treatment of lower urinary tract symptoms. BMC Urol. 2014; 14:63. doi: 10.1186/1471-2490-14-63.10.1186/1471-2490-14-63
- 30. Agbabiaka TB, Pittler MH, Wider B, et al. Serenoa repens (saw palmetto): a systematic review of adverse events. Drug Saf. 2009; 32(8):637-47. doi: 10.2165/00002018-200932080-00003.
Language: English
Page range: 123 - 129
Published on: Oct 7, 2017
Published by: Macedonian Academy of Sciences and Arts
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
Related subjects:
© 2017 Skender Saidi, Sotir Stavridis, Oliver Stankov, Sasho Dohcev, Sasho Panov, published by Macedonian Academy of Sciences and Arts
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.